Roche nabs an FDA OK for Gavreto, triggering a heavyweight bout with rivals at Eli Lilly
Four months after Eli Lilly’s Retevmo got the first FDA OK to treat RET-altered tumors, Roche and Blueprint Medicines are stepping into the ring with recently-approved Gavreto.
The Roche drug was approved on Friday to treat non-small cell lung cancer (NSCLC) patients with RET fusions, which are only present in about 1% to 2% of patients, according to Roche CMO Levi Garraway, who called the OK “an important step towards our goal of providing an effective treatment option for every person diagnosed with lung cancer, no matter how rare or hard-to-treat their type of disease.”
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 90,400+ biopharma pros reading Endpoints daily — and it's free.